Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-12-08
2011-11-08
Shameem, Golam M M (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S530000, C548S540000, C514S408000
Reexamination Certificate
active
08053465
ABSTRACT:
SummaryNovel bicycloester derivatives and pharmaceutically acceptable salts thereof have high DPP-IV inhibitory activity.Solving MeansThe novel bicycloester derivatives are represented by the general formula (1):Pharmaceutically acceptable salts thereof are also included (Example: (2S,4S)-1-[[(N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)).
REFERENCES:
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 5965764 (1999-10-01), Matsuoka et al.
patent: 6166063 (2000-12-01), Villhauer
patent: 6201132 (2001-03-01), Jenkins et al.
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6432969 (2002-08-01), Villhauer
patent: 6849622 (2005-02-01), Yasuda et al.
patent: 7138397 (2006-11-01), Yasuda et al.
patent: 7332487 (2008-02-01), Yasuda et al.
patent: 7514571 (2009-04-01), Fukuda et al.
patent: 7560569 (2009-07-01), Fukuda et al.
patent: 7754757 (2010-07-01), Fukuda et al.
patent: 2001/0025023 (2001-09-01), Carr
patent: 2001/0031780 (2001-10-01), Kanstrup et al.
patent: 2002/0006899 (2002-01-01), Pospisilik et al.
patent: 2002/0019411 (2002-02-01), Robl et al.
patent: 2002/0037829 (2002-03-01), Aronson et al.
patent: 2002/0049190 (2002-04-01), Bridger et al.
patent: 2002/0103384 (2002-08-01), Kanstrup et al.
patent: 2002/0110560 (2002-08-01), Demuth et al.
patent: 2002/0193390 (2002-12-01), Villhauer
patent: 2003/0100563 (2003-05-01), Edmondson et al.
patent: 2003/0105077 (2003-06-01), Kanstrup et al.
patent: 2003/0176357 (2003-09-01), Pospisilik et al.
patent: 2003/0225102 (2003-12-01), Sankaranarayanan
patent: 2004/0063935 (2004-04-01), Yasuda et al.
patent: 2004/0072892 (2004-04-01), Fukushima et al.
patent: 2004/0082607 (2004-04-01), Oi et al.
patent: 2004/0106655 (2004-06-01), Kitajima et al.
patent: 2004/0106802 (2004-06-01), Sankaranarayanan
patent: 2004/0121964 (2004-06-01), Madar et al.
patent: 2004/0152745 (2004-08-01), Jackson et al.
patent: 2004/0167133 (2004-08-01), Edmondson et al.
patent: 2004/0167341 (2004-08-01), Haffner et al.
patent: 2004/0171848 (2004-09-01), Haffner et al.
patent: 2004/0176428 (2004-09-01), Edmondson et al.
patent: 2004/0229926 (2004-11-01), Yasuda et al.
patent: 2004/0242636 (2004-12-01), Haffner et al.
patent: 2005/0054678 (2005-03-01), Yasuda et al.
patent: 2005/0070719 (2005-03-01), Belyakov et al.
patent: 2005/0130981 (2005-06-01), Aranyl et al.
patent: 2005/0148606 (2005-07-01), Kanstrup et al.
patent: 2005/0153973 (2005-07-01), Aranyl et al.
patent: 2005/0164989 (2005-07-01), Abe et al.
patent: 2005/0176771 (2005-08-01), Hayakawa et al.
patent: 2005/0245538 (2005-11-01), Kitajima et al.
patent: 2005/0266080 (2005-12-01), Desai et al.
patent: 2006/0142585 (2006-06-01), Thomas et al.
patent: 2006/0173056 (2006-08-01), Kitajima et al.
patent: 2006/0210627 (2006-09-01), Pfeffer et al.
patent: 2006/0241146 (2006-10-01), Yasuda et al.
patent: 2006/0270679 (2006-11-01), Edmondson et al.
patent: 2007/0112059 (2007-05-01), Fukushima et al.
patent: 2007/0112205 (2007-05-01), Fukushima et al.
patent: 2007/0167501 (2007-07-01), Fukuda et al.
patent: 2007/0265320 (2007-11-01), Fukuda et al.
patent: 2008/0038341 (2008-02-01), Kowalski et al.
patent: 2008/0050443 (2008-02-01), Kowalski et al.
patent: 2009/0048454 (2009-02-01), Asahina et al.
patent: 2002-356471 (2002-12-01), None
patent: 2002-356472 (2002-12-01), None
patent: 2003-520849 (2003-07-01), None
patent: 2004-2367 (2004-01-01), None
patent: 2004-2368 (2004-01-01), None
patent: 2004-26820 (2004-01-01), None
patent: 2004-503531 (2004-02-01), None
patent: 2006-160733 (2006-06-01), None
patent: 2008/239543 (2008-10-01), None
patent: 2008/290969 (2008-12-01), None
patent: 2009/114127 (2009-05-01), None
patent: 95/15309 (1995-06-01), None
patent: 98/19998 (1998-05-01), None
patent: 01/34594 (2001-05-01), None
patent: 01/55105 (2001-08-01), None
patent: 01/68603 (2001-09-01), None
patent: 02/07446 (2002-01-01), None
patent: 03/002553 (2003-01-01), None
patent: 03/004496 (2003-01-01), None
patent: 03/015775 (2003-02-01), None
patent: 03/017936 (2003-03-01), None
patent: 03/057144 (2003-07-01), None
patent: 03/057666 (2003-07-01), None
patent: 03/074500 (2003-09-01), None
patent: 03/080633 (2003-10-01), None
patent: 03/084940 (2003-10-01), None
patent: 03/095425 (2003-11-01), None
patent: 03/106456 (2003-12-01), None
patent: 04/000776 (2003-12-01), None
patent: 2004/007446 (2004-01-01), None
patent: 2004/026822 (2004-04-01), None
patent: 2004/099185 (2004-11-01), None
patent: 2005/067976 (2005-07-01), None
patent: 2005/117841 (2005-12-01), None
patent: 2006/021455 (2006-03-01), None
patent: 2006/040625 (2006-04-01), None
patent: 2006/043595 (2006-04-01), None
patent: 2006/078593 (2006-07-01), None
patent: 2006/135723 (2006-12-01), None
patent: 2007/102286 (2007-09-01), None
patent: 2008/096841 (2008-08-01), None
patent: 2008/114857 (2008-09-01), None
International Search Report issued Mar. 15, 2005 in International (PCT) Application No. PCT/JP2005/001377.
Deacon et al., “Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig”, American Journal of Physiology, v271, pp. E458-E464 (1996).
Knudsen et al., “Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-l-(7-36) amide after in vivo administration dogs, and it acts as an antagonist on the pancreatic receptor”, European Journal of Pharmacology, vol. 318, pp. 429-435 (1996).
Siegel et al., “Comparison of the effect of GIP and GLP-1 (7-36amide) on insulin release from rat pancreatic islets”, European Journal Clinical Investigation, v22, p. 154-157 (1992).
Kreymann et al., “Glucagon-like Peptide-1-7-36: A Physiological Incretin in Man”, Lancet, v2, p. 1300-1301 (1987).
Fehmann et al., “Insulinotropic Hormone Glucagon-like Peptide-I(7-37) Stimulation of Proinsulin Gene Expression and Proinsulin Biosynthesis in Insulinoma BTC-1 Cells”, Endocrinology, v130, p. 159-166 (1992).
Buteau et al., “Glucagon-like peptide-l-promotes DNA Synthesis, activates phospliyatidylinositol 3-kinase and increase transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells”, Diabetologia, v42, p. 856-864 (1999).
Egan, et al., “Glucagon-Like Peptide-1(7-36)Amide (GLP-1) Enhances Insulin-Stimulated Glucose Metabolism in 3T3-L1 Adipocytes: One of Several Potential Extrapancreatic Sites of GLP-1 Action”, Endocrinology, v135, p. 2070-2075 (1994).
Villanueva-Penacarrillo, et al., “Potent glycogenic effect of GLO-1(7-36)amide in rat skeletal muscle”, Diabetologia, v37, p. 1163 (1994).
Efendic, et al., “Glucagon-like Insulinotropic Peptide Has a Stronger Antidiabetogenic Effect than Glibenclamide”, Digestion, v54, p. 392-393 (1993).
Anvari et al., “Effects of GLP-1 on Gastric Emptying, Antropyloric Motility, and Transpyloric Flow in Response to a Nonnutrient Liquid”, Dig. Dis. Sci, v43, p. 1133-1140 (1998).
Holst et al., “Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes”, Diabetes, v47, pp. 1663-1670 (1998).
Balkan et al., “Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increase plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats”, Diabetologia, v42, pp. 1324-1331(1999).
Blazquez et al., “Selective Decrease of CD26 Expression in T Cells From HIV-1-Infected Individuals”, Journal of Immunology, v149, p. 3073-3077 (1992).
Subramanyam et al., “Mechanism of HIV-1 Tat Induced Inhibition of Antigen-Specific T Cell Responsiveness”, Journal of Immunology, v150, p. 2544-2553 (1993).
Schon et al., “Dipeptidyl Peptidase IV in the Immune System”, Biological Chemistry Hpppe-Seyler, p. 305-311 (1991).
Mattern et al., “Expression of CD26 (Dipeptidyl Peptidase IV) on Resting and Activated Human T-Lymphocytes”; Scandinavian Journal of Immunology, v33, p. 737-748 (1991).
Schon et al., “Dipeptidyl Peptidase IV in Human T
Asahina Yoshikazu
Fukuda Yasumichi
Matsui Toshiyuki
Murakami Koji
Ohata Kohei
Kyorin Pharmaceutical Co. Ltd.
Shameem Golam M M
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Bicycloester derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicycloester derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicycloester derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4284243